HC Wainwright Forecasts Surrozen FY2024 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – Investment analysts at HC Wainwright issued their FY2024 earnings estimates for Surrozen in a research report issued on Thursday, January 30th. HC Wainwright analyst M. Caufield expects that the company will earn ($8.49) per share for the year. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share. HC Wainwright also issued estimates for Surrozen’s Q4 2024 earnings at ($2.54) EPS, Q1 2025 earnings at ($2.71) EPS, Q2 2025 earnings at ($2.69) EPS, Q3 2025 earnings at ($2.67) EPS, Q4 2025 earnings at ($2.64) EPS, FY2025 earnings at ($10.71) EPS, FY2026 earnings at ($11.68) EPS, FY2027 earnings at ($13.81) EPS, FY2028 earnings at ($15.84) EPS and FY2029 earnings at ($16.24) EPS.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($2.77) by $2.33. The business had revenue of $10.00 million during the quarter.

Separately, Guggenheim upgraded shares of Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday, January 3rd.

Surrozen Stock Performance

SRZN opened at $11.31 on Monday. The company’s 50-day simple moving average is $11.65 and its two-hundred day simple moving average is $10.17. Surrozen has a 52-week low of $6.00 and a 52-week high of $18.17.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Surrozen stock. Stonepine Capital Management LLC raised its stake in shares of Surrozen, Inc. (NASDAQ:SRZN) by 66.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 110,000 shares of the company’s stock after purchasing an additional 43,916 shares during the period. Surrozen accounts for approximately 0.8% of Stonepine Capital Management LLC’s holdings, making the stock its 24th biggest position. Stonepine Capital Management LLC owned 3.43% of Surrozen worth $1,318,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.